PET-based uptake quantification presented significantly higher uptake in U87-MGvIII and GL261 brain tumors compared to non-tumor-bearing (NTB) mice (U87-MGvIII vs NTB brains: 2.4 ± 0.8 %ID/g vs 0.5 ± 0.3 %ID/g, p = 0.0205; GL261 vs NTB brains: 1.2 ± 0.3 %ID/g vs 0.3 ± 0.04 %ID/g,  p= 0.0023) or mice-bearing PD-L1 negative tumors (GL261 vs GL261PD-L1KO: 1.2 ± 0.3 %ID/g vs 0.5 ± 0.3 %ID/g, p = 0.0037) (Figure 2C and Supplementary Figure S3B). This evidence concerns the gene CD274 and neoplasm.